The goal of this Core is to provide hemangioma-derived cells and hemangioma tissue for analyses related to each of the three projects in this program project grant. Cells are purified, characterized by immunophenotyping, RT-PCR, and morphological analyses. The cells are cryopreserved in liquid nitrogen, and tracked by an Excel based inventory system. Over 100 hemangioma tissues from proliferating, involuting and involuted phases is available for RNA, DNA and tissue analyses. This represents an invaluable resource of studies on cellular and molecular mechanisms that cause infantile hemangioma. The Core will continue to add new primary cultures of hemangioma-derived cells, normal human microvascular EC and hemangioma tissues to this cell and tissue bank so that the spectrum of hemangioma samples is continuously replenished and available to all investigators working on this PPG. A specific focus of Core B in the requested funding period will be to fully characterize hemangioma-derived stem cells for use by investigators on this PPG. Training and technical support for endothelial cell isolation, expansion, and characterization will be available to the investigators on this PPG through the website, phone/e-mail communication, and hands-on training when required. In summary, this Core is an essential resource for the success of the Program Project.

Public Health Relevance

Core B will provide carefully characterized cell populations isolated from hemangioma tissue obtained when a hemangioma tumor is removed from a child as part of his/her clinical care. The tissue and the isolated cells provide powerful tools for the study of what causes the abnormal growth in hemangioma and also important tools for testing new treatments to prevent hemangioma formation and/or to accelerate involution.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Program Projects (P01)
Project #
5P01AR048564-10
Application #
8528332
Study Section
Special Emphasis Panel (ZAR1-EHB-F)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
10
Fiscal Year
2013
Total Cost
$122,614
Indirect Cost
$53,509
Name
Harvard University
Department
Type
DUNS #
047006379
City
Boston
State
MA
Country
United States
Zip Code
02115
Agarwal, Shailesh; Loder, Shawn; Brownley, Cameron et al. (2016) Inhibition of Hif1α prevents both trauma-induced and genetic heterotopic ossification. Proc Natl Acad Sci U S A 113:E338-47
Duan, Xuchen; Bradbury, Seth R; Olsen, Bjorn R et al. (2016) VEGF stimulates intramembranous bone formation during craniofacial skeletal development. Matrix Biol 52-54:127-40
Besschetnova, Tatiana Y; Ichimura, Takaharu; Katebi, Negin et al. (2015) Regulatory mechanisms of anthrax toxin receptor 1-dependent vascular and connective tissue homeostasis. Matrix Biol 42:56-73
Smadja, David M; Levy, Marilyne; Huang, Lan et al. (2015) Treprostinil indirectly regulates endothelial colony forming cell angiogenic properties by increasing VEGF-A produced by mesenchymal stem cells. Thromb Haemost 114:735-47
Huang, Lan; Nakayama, Hironao; Klagsbrun, Michael et al. (2015) Glucose transporter 1-positive endothelial cells in infantile hemangioma exhibit features of facultative stem cells. Stem Cells 33:133-45
Limaye, Nisha; Kangas, Jaakko; Mendola, Antonella et al. (2015) Somatic Activating PIK3CA Mutations Cause Venous Malformation. Am J Hum Genet 97:914-21
Nakayama, Hironao; Huang, Lan; Kelly, Ryan P et al. (2015) Infantile hemangioma-derived stem cells and endothelial cells are inhibited by class 3 semaphorins. Biochem Biophys Res Commun 464:126-32
Boscolo, Elisa; Limaye, Nisha; Huang, Lan et al. (2015) Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects. J Clin Invest 125:3491-504
Dellinger, Michael T; Garg, Nupur; Olsen, Bjorn R (2014) Viewpoints on vessels and vanishing bones in Gorham-Stout disease. Bone 63:47-52
Lee, D; Boscolo, E; Durham, J T et al. (2014) Propranolol targets the contractility of infantile haemangioma-derived pericytes. Br J Dermatol 171:1129-37

Showing the most recent 10 out of 50 publications